Results 241 to 250 of about 3,539,215 (285)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Donor Time to Death and DCD Liver Transplant Outcomes: Challenging the Dogma That Shorter Is Better. [PDF]

open access: yesTransplant Direct
Amarnath DR   +8 more
europepmc   +1 more source

Impact of a complex intervention in primary care for patients with palliative care needs in their healthcare utilization: a before-after study. [PDF]

open access: yesPrim Health Care Res Dev
Seiça Cardoso C   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy